What does ENDOCEUTICS do?

ENDOCEUTICS is a wholesaler in Brussel. Public Limited, started on 6 December 2018.

What is the address of ENDOCEUTICS?

The registered office of ENDOCEUTICS is located at Belliardstraat 40, 1040 Brussel.

Is ENDOCEUTICS still active?

Yes. According to the CBE (16 September 2026) ENDOCEUTICS is active, legal situation “Normale toestand”, started on 6 December 2018.

Is ENDOCEUTICS registered on Peppol?

Yes, ENDOCEUTICS is registered on the Peppol network with ID 0208:0715565040.

What is the enterprise number of ENDOCEUTICS?

The enterprise number of ENDOCEUTICS is BE0715565040.

When was ENDOCEUTICS founded?

ENDOCEUTICS was founded on 6 December 2018.

Who are the directors of ENDOCEUTICS?

According to the 2024 annual accounts, the directors of ENDOCEUTICS are: MYRIEL PHARMACEUTICALS ULC, MYRIEL PHARMACEUTICAL LLC, Endoceutics Pharma (USA) Inc, Endoceutics Inc.

Is ENDOCEUTICS a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 December 2018; 4 annual accounts filed, latest fiscal year 2024; 4 directors known from the annual account.

How much profit did ENDOCEUTICS make in 2024?

ENDOCEUTICS posted a profit after taxes of € 119,480 in financial year 2024.

What is the revenue of ENDOCEUTICS?

As a small company, ENDOCEUTICS is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 123,176.

ENDOCEUTICS (Public Limited) - Brussel - BE0715565040

Dossier ENDOCEUTICS, printed on 16 September 2026 from databakkes.be/en/0715565040/endoceutics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 61 % of short-term debt in 2024; threshold 65 %.
Busy address KBO

97 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2024

ENDOCEUTICS from Brussel, company number BE0715565040, closed financial year 2024 with a result of € 119,480 after tax. For that financial year ENDOCEUTICS recorded a gross margin of € 123,176 and equity of € -114,099. Compared with financial year 2023, the result moved from € 9,374 to € 119,480. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 14, 2025.

What it is worth Caution

€ -114,099

▲ € 119,480 vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 119,480

▲ € 110,107 vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 421,485

▲ € 369,745 vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € -175,599.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3.2 million

▲ € 2.5 million vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 69,141

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ -39,501 Gross margin 2021: € -39,501 First fiscal year in the series	€ 148,685 Gross margin 2022: € 148,685 ▲ € 188,186 vs 2021 (€ -39,501) Favourable step	€ 12,840 Gross margin 2023: € 12,840 ▼ 91% vs 2022 (€ 148,685) Unfavourable step	€ 123,176 Gross margin 2024: € 123,176 ▲ € 110,336 vs 2023 (€ 12,840) Favourable step	▲ € 110,336
Profit after taxes	€ -34,384 Profit after taxes 2021: € -34,384 First fiscal year in the series	€ 148,005 Profit after taxes 2022: € 148,005 ▲ € 182,389 vs 2021 (€ -34,384) Favourable step	€ 9,374 Profit after taxes 2023: € 9,374 ▼ 94% vs 2022 (€ 148,005) Unfavourable step	€ 119,480 Profit after taxes 2024: € 119,480 ▲ € 110,107 vs 2023 (€ 9,374) Favourable step	▲ € 110,107
Equity	€ -390,958 Equity 2021: € -390,958 First fiscal year in the series	€ -242,953 Equity 2022: € -242,953 ▲ € 148,005 vs 2021 (€ -390,958) Favourable step	€ -233,580 Equity 2023: € -233,580 ▲ € 9,374 vs 2022 (€ -242,953) Favourable step	€ -114,099 Equity 2024: € -114,099 ▲ € 119,480 vs 2023 (€ -233,580) Favourable step	▲ € 119,480
Total debts	€ 1,109,166 Total debts 2021: € 1,109,166 First fiscal year in the series	€ 884,335 Total debts 2022: € 884,335 ▼ 20% vs 2021 (€ 1,109,166) Favourable step	€ 1,272,172 Total debts 2023: € 1,272,172 ▲ 44% vs 2022 (€ 884,335) Unfavourable step	€ 4,819,774 Total debts 2024: € 4,819,774 ▲ 279% vs 2023 (€ 1,272,172) Unfavourable step	▲ 279%
Cash	€ 353,652 Cash 2021: € 353,652 First fiscal year in the series	€ 256,457 Cash 2022: € 256,457 ▼ 27% vs 2021 (€ 353,652) Unfavourable step	€ 51,740 Cash 2023: € 51,740 ▼ 80% vs 2022 (€ 256,457) Unfavourable step	€ 421,485 Cash 2024: € 421,485 ▲ € 369,745 vs 2023 (€ 51,740) Favourable step	▲ € 369,745
Retained profit	€ -452,458 Retained profit 2021: € -452,458 First fiscal year in the series	€ -304,453 Retained profit 2022: € -304,453 ▲ € 148,005 vs 2021 (€ -452,458) Favourable step	€ -295,080 Retained profit 2023: € -295,080 ▲ € 9,374 vs 2022 (€ -304,453) Favourable step	€ -175,599 Retained profit 2024: € -175,599 ▲ € 119,480 vs 2023 (€ -295,080) Favourable step	▲ € 119,480
Balance sheet total	€ 718,207 Balance sheet total 2021: € 718,207 First fiscal year in the series	€ 641,382 Balance sheet total 2022: € 641,382 ▼ 11% vs 2021 (€ 718,207) Unchanged	€ 1,038,593 Balance sheet total 2023: € 1,038,593 ▲ 62% vs 2022 (€ 641,382) Unchanged	€ 4,705,675 Balance sheet total 2024: € 4,705,675 ▲ € 3.7 million vs 2023 (€ 1,038,593) Unchanged	▲ € 3.7 million

Key figures of ENDOCEUTICS, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to ENDOCEUTICS?

What happened at ENDOCEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 14, 2025 New annual accounts for financial year 2024: profit of € 119,480 (▲ € 110,107 vs 2023). filed late Source: NBB ↗
2023 MYRIEL PHARMACEUTICALS ULC became a director. NBB
2023 MYRIEL PHARMACEUTICAL LLC became a director. NBB
2023 Endoceutics Pharma (USA) Inc stepped down as director. NBB
2023 Endoceutics Inc stepped down as director. NBB
2018 Endoceutics Pharma (USA) Inc became a director. NBB
2018 Endoceutics Inc became a director. NBB
Dec 6, 2018 Start of the company according to the CBE. KBO

In short

From € 34,384 loss in 2021 to € 119,480 profit in 2024.

Best year ever: 2022, with € 148,005 profit.

Original PDFs at the National Bank ↗

A new publication or filing at ENDOCEUTICS? We notify you, reason included.

Follow ENDOCEUTICS

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

MYRIEL PHARMACEUTICAL LLC 100%

MYRIEL PHARMACEUTICALS ULC 0%

ENDOCEUTICS

Behind ENDOCEUTICS are MYRIEL PHARMACEUTICALS ULC and MYRIEL PHARMACEUTICAL LLC. The shares are held by MYRIEL PHARMACEUTICAL LLC (100%) and MYRIEL PHARMACEUTICALS ULC (0%).

See the full network in the app

Directors

According to the 2024 annual accounts

MYRIEL PHARMACEUTICALS ULC

Director · represented by APURVA OM SARAF

since 2023

MYRIEL PHARMACEUTICAL LLC

Director · represented by SERGE ILIN-SCHNEIDER

since 2023

Endoceutics Pharma (USA) Inc

Director · represented by Turpin Dennis

since 2018 · until 2023

Endoceutics Inc

Director · represented by Claude Labrie

since 2018 · until 2023

Shareholders

MYRIEL PHARMACEUTICAL LLC

100%

MYRIEL PHARMACEUTICALS ULC

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Belliardstraat 40

1040 Brussel

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 97 companies are registered at this address.

All companies at this address →

ASSOCIATION EUROPEENNE DU CHARBON ET DU LIGNITE

The European Petrochemical Association

€ 2.7 million gross margin · 2025

CONSEIL EUROPEEN DE L'INDUSTRIE CHIMIQUE - EUROPEAN CHEMICAL INDUSTRY COUNCIL

€ 4.4 million revenue · 2025

CBRE Investment Management Belgium

€ 4.2 million revenue · 2025

Plastics Europe

+92 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0715.565.040
VAT number: BE 0715.565.040
Registered office: Belliardstraat 40, 1040 Brussel
Names & denominations: ENDOCEUTICS
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 6 December 2018
Peppol: Active · Active since 16 Dec 2025
Activities · NACE: Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗